pyrazines has been researched along with Pneumonia, Viral in 66 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 66 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J; Qi, C; Shen, L; Wang, Y; Zhang, Q | 1 |
| Dong, L; Gao, J; Hu, S | 1 |
| Duan, Y; Zhou, C; Zhu, HL | 1 |
| Jensen, JD; Lynch, M | 1 |
| Chan, MCW; Chen, D; Cheung, PP; Choy, KT; Chu, DKW; Huang, X; Hui, KPY; Kaewpreedee, P; Peiris, M; Sia, SF; Wong, AY; Yen, HL | 1 |
| Cutrell, JB; Jodlowski, TZ; Monogue, ML; Sanders, JM | 1 |
| Şimşek Yavuz, S; Ünal, S | 1 |
| Costanzo, M; De Giglio, MAR; Roviello, GN | 1 |
| Hsueh, PR; Jean, SS; Lee, PI | 1 |
| Ge, J; Li, H; Liu, Z | 1 |
| Alkindi, N; Mazer-Amirshahi, M; Mehta, N; Pourmand, A | 1 |
| Ahsan, W; Alhazmi, HA; Bratty, MA; Javed, S; Najmi, A | 1 |
| Chong, EA; Davids, MS; Mato, AR; Roeker, LE; Schuster, SJ; Shadman, M | 1 |
| de Lamballerie, X; Eloy, P; Guedj, J; Malvy, D; Mentré, F; Solas, C; Touret, F | 1 |
| Chen, XP; Du, YX | 1 |
| Delang, L; Neyts, J | 1 |
| Lin, SX; Stephen, P; Thériault, JF; Wang, R; Zhang, WF | 1 |
| Baggett, MV; Rhee, EP; Shepard, JO; Sise, ME; Stevens, JS | 1 |
| Coomes, EA; Haghbayan, H | 1 |
| Bhalla, S; Gabrilove, J; Sigel, K; Thibaud, S; Tremblay, D; Zimmerman, B | 1 |
| Alper, S; Altuğ, E; Çelebi, İ; Demirkesen, C; Ferhanoğlu, B; Kocatürk, E; Taşkın, B; Vural, S | 1 |
| Eto, M; Fujita, H; Hashida, T; Ikesue, H; Irie, K; Muroi, N; Nakagawa, A; Tamura, R; Tomii, K | 1 |
| Chen, K; Couban, RJ; Du, X; Gong, X; Guyatt, G; He, N; Ibrahim, QI; Li, X; Li, Y; Liu, F; Liu, J; Liu, W; Shen, N; Tang, Q; Wu, Z; Xu, X; Ye, Z; Ying, Y; Zhai, S; Zhang, Q; Zhang, Y; Zhou, P | 1 |
| Campos, L; Gouveia, CC | 1 |
| Li, J; Wang, G; Wu, Z; Zhang, C; Zhao, H | 1 |
| Baselga, J; Chung, KK; Collen, J; Desai, JV; Goy, A; Hamdy, A; Izumi, R; Lionakis, MS; Monticelli, MA; Roschewski, M; Rose, K; Roshon, M; Roswarski, J; Sharman, JP; Staudt, LM; Wilson, WH; Wright, GW; Wrzesinski, SH; Zarakas, MA | 1 |
| Chen, D; Dong, L; Pan, X; Peng, C; Yang, L | 1 |
| Abe, T; Anzai, N; Mishima, E; Miyazaki, M | 1 |
| Li, C; Ren, L; Wang, L | 1 |
| Fenioux, C; Funck-Brentano, C; Gligorov, J; Gougis, P; Solas, C; Spano, JP; Veyri, M | 1 |
| Ikeda, T; Kondo, Y; Miyazaki, S; Yamashita, R | 1 |
| Martinez, MA | 1 |
| Li, Z; Liu, Y; Wang, D | 1 |
| Bellutti-Enders, F; Hartmann, K; Jamiolkowski, D; Leuppi-Taegtmeyer, A; Manjaly Thomas, ZR; Scherer Hofmeier, K; Steveling-Klein, E | 1 |
| Carvalho Junior, RN; J C Neto, AM; Martins, AY; Reis, AF; S Costa, JF; Silva Arouche, TD | 1 |
| Han, YJ; Ji, XY; Li, XX; Ma, CY; Ren, ZG; Wu, DD; Yan, JL | 1 |
| Hase, R; Ishida, K; Kurata, R; Kurita, T; Mito, H; Muranaka, E | 1 |
| Carroll, M; Chalmers, JD; De Soyza, A; Dixon, R; Doherty, J; Duncan, G; Felton, T; Gordon, A; Griffiths, G; Ho, LP; Lewis, KE; Martinez-Alier, N; McGarvey, L; O'Kelly, M; Page, C; Phekoo, K; Read, RC; Shankar-Hari, M; Singh, D; Summers, C; Sykes, J; Walles, R; Wilkinson, T | 1 |
| Arab-Zozani, M; Ghoddoosi-Nejad, D; Hassanipour, S | 1 |
| Deshpande, GA; Kaname, S; Kishimoto, M; Komagata, Y; Kurai, D; Ono, K; Shimasaki, T; Uchida, H | 1 |
| Al-Yamani, MJ; Asdaq, SMB; Jomah, S | 1 |
| Ijaz, M; Khan, M; Kharaba, ZJ; Murtaza, G; Shamim, S | 1 |
| Hifumi, T; Ishimatsu, S; Isokawa, S; Otani, N | 1 |
| Inoue, KI; Sagawa, T; Takano, H | 1 |
| Fujii, H; Hiraoka, N; Horiguchi, M; Matsuyama, A; Omura, A; Ono, S; Shiotsu, S; Suga, Y; Takumi, C; Tanaka, S; Tsuji, T; Yuba, T | 1 |
| Islam, MA; Nasir, M; Perveen, RA; Saha, SK; Selina, F; Talha, KA | 1 |
| Barfuss, P; Demirbag, S; Khan, KS; Le, TK; Ng, WL; Paris, C; Robson, F; Rocchi, P | 1 |
| Aykaç, K; Cengiz, AB; Ceyhan, M; Cura Yayla, BC; Derin Oygar, P; İlbay, S; Karahan, S; Kukul, MG; Laçinel Gürlevik, S; Özsürekçi, Y | 1 |
| Chae, H; Jeong, HJ; Jeong, K; Kim, S; Lee, G; Min, S; Namgoong, SK | 1 |
| Fukui, Y; Hatano, T; Kawagishi, T; Kawasuji, H; Kuwano, H; Miyajima, Y; Morinaga, Y; Okudera, H; Sakamaki, I; Shibuya, T; Takegoshi, Y; Tani, H; Ueno, A; Wakasugi, M; Yamamoto, Y | 1 |
| Canard, B; Coutard, B; Decroly, E; Fattorini, V; Ferron, F; Huchting, J; Le, NT; Meier, C; Peersen, O; Piorkowski, G; Selisko, B; Shannon, A; Touret, F | 1 |
| Aydın, A; Çekiç, D; Dheir, H; Genc, AB; Karabay, O; Kocayigit, H; Koroglu, M; Şenocak, D; Varım, C; Yaylaci, S | 1 |
| McCullough, PA | 1 |
| Budhathoki, P; Khadka, S; Pokharel, N; Rashmi, P; Shah, PB; Shrestha, DB | 1 |
| Cao, R; Fu, D; Li, W; Wen, J; Zhao, L; Zhong, W | 1 |
| Emanuela, C; Francesco, L; Giorgia, G; Pasquale, N; Roberto, P; Sara, D | 1 |
| Abdelaziz, MR; Abu-Melha, S; Edrees, MM; Elfiky, AA; Gomha, SM; Riyadh, SM | 1 |
| Anglaret, X; Binquet, C; Bouchet, S; Crémer, A; Darnaud, T; Dupouy, J; Duvignaud, A; Gimbert, A; Joseph, JP; Journot, V; Lebeaux, D; Lebel, J; Lefèvre, B; Lhomme, E; Malvy, D; Michel, JF; Nguyen, D; Onaisi, R; Orne-Gliemann, J; Peiffer-Smadja, N; Piroth, L; Pistone, T; Poitrenaud, D; Richert, L; Roussillon, C; Sitta, R; Thiébaut, R; Wittkop, L | 1 |
| Cheng, A; Gardiner, B; Hoy, JF; Lau, JSY; Lee, SJ; McMahon, JH; Molton, JS; Peleg, AY; Rogers, BA; Roney, J; Sasadeusz, J; Trubiano, J | 1 |
| Bazram, A; Fathalipour, M; Hassaniazad, M; Hassanipour, S | 1 |
| Alaskar, A; Aldibasi, O; Alharbi, A; Aljeraisy, M; AlJohani, S; Almaghaslah, M; Almutairi, B; Alothman, A; Alqahtani, H; Alsaedy, A; Arabi, Y; Bosaeed, M; Bouchama, A; Hussein, M; Mahmoud, E; Nashabat, M | 1 |
| Hase, R; Ishida, K; Kurita, T; Mito, H; Muranaka, E; Sasazawa, H; Yano, Y | 1 |
| Boku, R; Hirouchi, T; Iwata, K; Kamachi, K; Mashima, D; Matsumoto, T; Morikawa, M; Ota, S; Sato, T; Shinada, K; Shinkai, M; Shinoda, M; Yoshida, Y | 1 |
| Kutlu, Ö; Yılmaz, Ş | 1 |
| Avcı, İY; Çetinkaya, RA; Demirtürk, N; Eser, F; Güner, R; Karalezli, A; Kayaaslan, B; Konya, P; Okumuş, N; Orhan, S; Savaşçı, Ü; Şaylan, B; Taşkın, G; Yamanel, L; Yılmaz, G | 1 |
| Fukuoka, S; Imai, T; Kishaba, T; Maeda, A; Nabeya, D; Nagano, H; Narita, M; Shiiki, S; Takakura, S; Yokoyama, S | 1 |
24 review(s) available for pyrazines and Pneumonia, Viral
| Article | Year |
|---|---|
Clinical trial analysis of 2019-nCoV therapy registered in China.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Disease Management; Disease Outbreaks; Drugs, Chinese Herbal; Humans; Medicine, Chinese Traditional; Pandemics; Pneumonia, Viral; Practice Guidelines as Topic; Pyrazines; SARS-CoV-2 | 2020 |
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Immunoglobulins; Immunologic Factors; Indoles; Lopinavir; Oseltamivir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Withholding Treatment | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Humans; Hydroxychloroquine; Ivermectin; Lopinavir; Nitro Compounds; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2; Thiazoles | 2020 |
Treatment options for COVID-19: The reality and challenges.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Teicoplanin | 2020 |
Scientific research progress of COVID-19/SARS-CoV-2 in the first five months.
Topics: Adenosine Monophosphate; Alanine; Amides; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; COVID-19 Testing; COVID-19 Vaccines; Disease Progression; Gene Expression Regulation; Host-Pathogen Interactions; Humans; Immunization, Passive; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Pyrazines; SARS-CoV-2; Severity of Illness Index; Spike Glycoprotein, Coronavirus; Viral Vaccines | 2020 |
Pharmacotherapy in COVID-19; A narrative review for emergency providers.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Emergency Service, Hospital; Humans; Hydroxychloroquine; Interleukin-6; Pandemics; Pneumonia, Viral; Pyrazines; Randomized Controlled Trials as Topic; SARS-CoV-2 | 2020 |
Treatment of SARS-CoV-2: How far have we reached?
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Darunavir; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferon-alpha; Interferon-beta; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
Medical treatment options for COVID-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Cytochrome P-450 CYP3A Inhibitors; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunologic Factors; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Recombinant Proteins; RNA, Viral; SARS-CoV-2 | 2020 |
Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
Topics: Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Evidence-Based Medicine; Humans; Hydroxychloroquine; Indoles; Influenza, Human; Lopinavir; Observational Studies as Topic; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Coronavirus Disease 2019: Clinical Review.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Azithromycin; Betacoronavirus; Blood Coagulation Disorders; China; Chiroptera; Chloroquine; Coronavirus Infections; COVID-19; Glucocorticoids; Humans; Hydroxychloroquine; Infectious Disease Incubation Period; Lopinavir; Lung; Pandemics; Pneumonia, Viral; Prognosis; Pyrazines; Radiography, Thoracic; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2; Symptom Assessment | 2020 |
Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Drugs, Chinese Herbal; Humans; Indoles; Interferons; Lopinavir; Lung; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Survival Analysis | 2020 |
Uric Acid Elevation by Favipiravir, an Antiviral Drug.
Topics: Aldehyde Oxidase; Amides; Antiviral Agents; Biotransformation; Coronavirus Infections; COVID-19; Drug Interactions; Humans; Hyperuricemia; Kidney; Kidney Diseases; Molecular Structure; Organic Anion Transport Protein 1; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Organic Cation Transport Proteins; Pandemics; Pneumonia, Viral; Pyrazines; Uric Acid; Xanthine Oxidase | 2020 |
Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; Drug Combinations; Drugs, Chinese Herbal; Humans; Hydroxychloroquine; Indoles; Interferons; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Survival Analysis; Teicoplanin | 2020 |
Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Administration Schedule; Drug Combinations; Drug Repositioning; Humans; Hydroxychloroquine; Interferons; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Randomized Controlled Trials as Topic; Ribavirin; Ritonavir; SARS-CoV-2; Survival Analysis; Treatment Outcome | 2020 |
An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.
Topics: Adenosine Monophosphate; Alanine; Amides; Angiotensin-Converting Enzyme Inhibitors; Antimalarials; Antiviral Agents; Betacoronavirus; Biomedical Research; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; Drug Combinations; Drug Development; Drugs, Chinese Herbal; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Drug Hypersensitivity; Humans; Immunity, Innate; Immunologic Factors; Indoles; Infliximab; Interleukin 1 Receptor Antagonist Protein; Nitriles; Pandemics; Pneumonia, Viral; Pyrazines; Pyrazoles; Pyrimidines; SARS-CoV-2; Severity of Illness Index | 2020 |
Advances and challenges in the prevention and treatment of COVID-19.
Topics: Amides; Antibodies, Monoclonal; Antiviral Agents; Betacoronavirus; Chloroquine; Chlorpromazine; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cyclophilins; Drug Development; Drug Repositioning; Drugs, Chinese Herbal; Endocytosis; Humans; Immune Sera; Interferon Inducers; Nucleic Acid Synthesis Inhibitors; Pandemics; Pneumonia, Viral; Pyrazines; Resveratrol; SARS-CoV-2; Viral Vaccines | 2020 |
Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Humans; Indoles; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
Potential strategies for combating COVID-19.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; COVID-19 Vaccines; Cytokine Release Syndrome; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Immunologic Factors; Indoles; Interleukin 1 Receptor Antagonist Protein; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2; Severity of Illness Index; Viral Vaccines | 2020 |
High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review : High levels of anti-SSA/Ro antibodies in COVID-19.
Topics: Aged; Amides; Antibodies, Antinuclear; Antiviral Agents; Benzamidines; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Glucocorticoids; Guanidines; Humans; Hydroxychloroquine; Lung Diseases, Interstitial; Male; Methylprednisolone; Pandemics; Pneumonia, Viral; Pregnenediones; Pyrazines; Recovery of Function; Respiratory Distress Syndrome; Respiratory Insufficiency; SARS-CoV-2; Severity of Illness Index; Tomography, X-Ray Computed | 2020 |
Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2.
Topics: Amides; Antiviral Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2; Treatment Outcome | 2020 |
Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Cytidine; Genome, Viral; Humans; Hydroxylamines; Molecular Targeted Therapy; Mutation; Pandemics; Pneumonia, Viral; Pyrazines; Ribonucleosides; RNA, Viral; SARS-CoV-2; Severity of Illness Index; Transcription, Genetic; Viral Nonstructural Proteins; Virus Replication | 2020 |
Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis.
Topics: Amides; Antiviral Agents; Betacoronavirus; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Databases, Factual; DNA-Directed RNA Polymerases; Enzyme Inhibitors; Humans; Pandemics; Pneumonia, Viral; Pyrazines; Randomized Controlled Trials as Topic; SARS-CoV-2; Standard of Care; Treatment Outcome | 2020 |
Current treatment of COVID-19 in renal patients: hope or hype?
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal; Cobicistat; Coronavirus Infections; COVID-19; Darunavir; Drug Combinations; Humans; Kidney; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Renal Insufficiency, Chronic; Renal Replacement Therapy; Ritonavir | 2020 |
8 trial(s) available for pyrazines and Pneumonia, Viral
| Article | Year |
|---|---|
Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19.
Topics: Adult; Aged; Amides; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Critical Illness; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Intubation, Gastrointestinal; Male; Pandemics; Pneumonia, Viral; Pyrazines; Respiration, Artificial; SARS-CoV-2; Severity of Illness Index; Suspensions; Tablets; Treatment Outcome | 2020 |
The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Pandemics; Pneumonia, Viral; Pyrazines; Randomized Controlled Trials as Topic; RNA, Viral; SARS-CoV-2; Treatment Outcome; Young Adult | 2020 |
ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised
Topics: Antiviral Agents; Benzamides; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Hospitalization; Humans; Pandemics; Pneumonia, Viral; Pyrazines; Randomized Controlled Trials as Topic; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Standard of Care | 2020 |
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to R
Topics: Aged; Aged, 80 and over; Amides; Antihypertensive Agents; Antimalarials; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Tolerance; Feasibility Studies; France; Hospitalization; Humans; Hydroxychloroquine; Imatinib Mesylate; Luxembourg; Outpatients; Pandemics; Pneumonia, Viral; Protein Kinase Inhibitors; Pyrazines; Risk Reduction Behavior; SARS-CoV-2; Telmisartan; Therapies, Investigational; Treatment Outcome | 2020 |
An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.
Topics: Amides; Antiviral Agents; Australia; Betacoronavirus; Biomarkers; Clinical Protocols; Coronavirus Infections; COVID-19; Female; Hospitalization; Humans; Male; Pandemics; Placebos; Pneumonia, Viral; Pyrazines; Safety; SARS-CoV-2; Treatment Outcome | 2020 |
Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
Topics: Adult; Amides; Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Interferons; Iran; Lopinavir; Male; Pandemics; Pneumonia, Viral; Pyrazines; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Severity of Illness Index; Treatment Outcome; Viral Load | 2020 |
A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Topics: Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Host-Pathogen Interactions; Humans; Hydroxychloroquine; Inpatients; Male; Multicenter Studies as Topic; Pandemics; Pneumonia, Viral; Pyrazines; Randomized Controlled Trials as Topic; SARS-CoV-2; Saudi Arabia; Time Factors; Treatment Outcome | 2020 |
Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients.
Topics: Aged; Amides; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; Azithromycin; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Ivermectin; Male; Middle Aged; Pneumonia, Viral; Prospective Studies; Pyrazines; Single-Blind Method; Treatment Outcome | 2021 |
34 other study(ies) available for pyrazines and Pneumonia, Viral
| Article | Year |
|---|---|
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Studies as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Discovery; Humans; Indoles; Pandemics; Pneumonia, Viral; Pyrazines; Ribonucleotides; SARS-CoV-2; Virus Replication | 2020 |
Advance of promising targets and agents against COVID-19 in China.
Topics: Adenine; Adenosine Monophosphate; Alanine; Amides; Antimalarials; Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Cobicistat; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cysteine Endopeptidases; Dibenzothiepins; Drug Combinations; Drug Discovery; Drug Therapy, Combination; Emtricitabine; Humans; Hydroxychloroquine; Indoles; Lopinavir; Medicine, Chinese Traditional; Morpholines; Oseltamivir; Oxazines; Pandemics; Pneumonia, Viral; Pyrazines; Pyridines; Pyridones; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Tenofovir; Thiepins; Triazines; Viral Nonstructural Proteins | 2020 |
Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy.
Topics: Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Models, Genetic; Mutation; Mutation Accumulation; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2 | 2020 |
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antimetabolites; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Emetine; Epithelial Cells; Homoharringtonine; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; SARS-CoV-2; Vero Cells; Virus Replication | 2020 |
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Darunavir; Drug Combinations; Humans; Hydroxychloroquine; Indoles; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte).
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Inflammation; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Macrophages; Pandemics; Piperidines; Pneumonia, Viral; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; SARS-CoV-2 | 2020 |
Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2.
Topics: Amides; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus | 2020 |
Response to "Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2".
Topics: Amides; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus | 2020 |
Novel Coronavirus Polymerase and Nucleotidyl-Transferase Structures: Potential to Target New Outbreaks.
Topics: Adenine; Adenosine; Amides; Antiviral Agents; Betacoronavirus; Binding Sites; Coronavirus Infections; COVID-19; Humans; Molecular Docking Simulation; Nucleotidyltransferases; Pandemics; Pneumonia, Viral; Protein Structure, Tertiary; Pyrazines; Pyrrolidines; RNA-Dependent RNA Polymerase; SARS-CoV-2 | 2020 |
Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury.
Topics: Acute Kidney Injury; Adenosine Monophosphate; Aged; Alanine; Amides; Anti-Inflammatory Agents; Anticoagulants; Antiviral Agents; Betacoronavirus; Continuous Renal Replacement Therapy; Coronavirus Infections; COVID-19; Creatinine; Humans; Hypertension; Lung; Male; Obesity; Pandemics; Pneumonia, Viral; Pyrazines; Radiography, Thoracic; SARS-CoV-2 | 2020 |
Favipiravir, an antiviral for COVID-19?
Topics: Amides; Antiviral Agents; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2 | 2020 |
Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pandemics; Piperidines; Pneumonia, Viral; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; SARS-CoV-2 | 2020 |
Coronavirus 19 presenting with atypical Sweet's syndrome.
Topics: Amides; Antibodies, Monoclonal, Humanized; Biopsy, Needle; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Diagnosis, Differential; Erythema; Facial Dermatoses; Female; Fever; Humans; Immunohistochemistry; Middle Aged; Pandemics; Pneumonia, Viral; Pyrazines; Real-Time Polymerase Chain Reaction; Sweet Syndrome; Tomography, X-Ray Computed | 2020 |
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.
Topics: Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Critical Illness; Female; Follow-Up Studies; Humans; Inflammation; Interleukin-6; Male; Middle Aged; Monocytes; Pandemics; Pneumonia, Viral; Prospective Studies; Pyrazines; Respiration, Artificial; SARS-CoV-2; Treatment Outcome | 2020 |
Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
Topics: Amides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Antiviral Agents; Betacoronavirus; Chemical and Drug Induced Liver Injury; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 Enzyme System; Drug Combinations; Drug Interactions; Histone Deacetylase Inhibitors; Humans; Hydroxychloroquine; Immunosuppression Therapy; Kidney Diseases; Long QT Syndrome; Lopinavir; Neoplasms; Pandemics; Pneumonia, Viral; Poly(ADP-ribose) Polymerase Inhibitors; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
Coinfection with SARS-CoV-2 and influenza A virus.
Topics: Amides; Anti-Bacterial Agents; Antiviral Agents; Betacoronavirus; Coinfection; Coronavirus Infections; COVID-19; Diagnosis, Differential; Glucocorticoids; Humans; Influenza A virus; Influenza, Human; Lung; Male; Middle Aged; Pandemics; Pneumonia, Viral; Pregnenediones; Pyrazines; Radiography; Real-Time Polymerase Chain Reaction; SARS-CoV-2 | 2020 |
Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.
Topics: Adenine; Adenosine; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Binding Sites; Chloroquine; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cysteine Endopeptidases; Drug Interactions; Humans; Hydrogen Bonding; Hydroxychloroquine; Ligands; Molecular Docking Simulation; Nanotechnology; Pandemics; Pneumonia, Viral; Protease Inhibitors; Pyrazines; Pyrrolidines; Ribavirin; SARS-CoV-2; Static Electricity; Viral Nonstructural Proteins | 2020 |
Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019.
Topics: Adult; Amides; Antiviral Agents; Arthritis, Gouty; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Hyperuricemia; Lung; Male; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2; Uric Acid | 2020 |
Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials.
Topics: Adult; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Male; Meta-Analysis as Topic; Pandemics; Pneumonia, Viral; Pyrazines; Research Design; SARS-CoV-2; Systematic Reviews as Topic; Treatment Outcome | 2020 |
Reactive arthritis after COVID-19 infection.
Topics: Adrenal Cortex Hormones; Amides; Ankle Joint; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Arthritis, Reactive; Arthrocentesis; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Injections, Intra-Articular; Male; Middle Aged; Pandemics; Pneumonia, Viral; Prohibitins; Pyrazines; Respiration, Artificial; Respiratory Distress Syndrome; SARS-CoV-2 | 2020 |
Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients.
Topics: Amides; Benzamidines; Betacoronavirus; Coronavirus Infections; COVID-19; Critical Illness; Guanidines; Humans; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2 | 2020 |
Preventing the clinical manifestations and disease progression of coronavirus disease using clinically proven protease inhibitors.
Topics: Amides; Benzamidines; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; Critical Illness; Disease Progression; Guanidines; Humans; Pandemics; Pneumonia, Viral; Protease Inhibitors; Pyrazines; SARS-CoV-2 | 2020 |
Characteristics and Management of Children with COVID-19 in Turkey
Topics: Adolescent; Amides; Antimalarials; Antiviral Agents; Betacoronavirus; Child; Child, Preschool; Coronavirus Infections; COVID-19; Extracorporeal Membrane Oxygenation; Female; Humans; Hydroxychloroquine; Infant; Infant, Newborn; Intensive Care Units, Pediatric; Length of Stay; Male; Pandemics; Patient Acuity; Pneumonia, Viral; Pyrazines; Respiration, Artificial; Retrospective Studies; SARS-CoV-2; Treatment Outcome; Turkey | 2020 |
Signal amplification by reversible exchange for COVID-19 antiviral drug candidates.
Topics: Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Discovery; Humans; Lopinavir; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
Monitoring of viral load by RT-PCR caused decision making to continue ECMO therapy for a patient with COVID-19.
Topics: Amides; Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Decision Making; Extracorporeal Membrane Oxygenation; Hospitalization; Humans; Lung; Male; Middle Aged; Pandemics; Pneumonia, Viral; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome; Viral Load | 2020 |
Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis.
Topics: Amides; Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Coronavirus Infections; Coronavirus RNA-Dependent RNA Polymerase; COVID-19; COVID-19 Drug Treatment; Models, Molecular; Mutagenesis; Pandemics; Pneumonia, Viral; Pyrazines; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Sequence Analysis; Vero Cells; Viral Nonstructural Proteins; Virus Replication | 2020 |
The effects of favipiravir on hematological parameters of covıd-19 patients.
Topics: Adult; Aged; Aged, 80 and over; Amides; Betacoronavirus; CD4 Lymphocyte Count; Coronavirus Infections; COVID-19; Female; Hemoglobins; Humans; Leukocyte Count; Male; Middle Aged; Pandemics; Platelet Count; Pneumonia, Viral; Pyrazines; Retrospective Studies; SARS-CoV-2 | 2020 |
Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).
Topics: Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral; Prospective Studies; Pyrazines; SARS-CoV-2; Severe Acute Respiratory Syndrome | 2020 |
Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series.
Topics: Administration, Oral; Aged; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Male; Middle Aged; Pandemics; Pneumonia, Viral; Pyrazines; RNA, Viral; SARS-CoV-2; Virus Shedding | 2020 |
Clean Grinding Technique: A Facile Synthesis and In Silico Antiviral Activity of Hydrazones, Pyrazoles, and Pyrazines Bearing Thiazole Moiety against SARS-CoV-2 Main Protease (M
Topics: Antiviral Agents; Betacoronavirus; Binding Sites; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; Cysteine Endopeptidases; Drug Discovery; Humans; Hydrazones; Molecular Docking Simulation; Molecular Dynamics Simulation; Pandemics; Pneumonia, Viral; Protease Inhibitors; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Pyrazines; Pyrazoles; SARS-CoV-2; Thermodynamics; User-Computer Interface; Viral Nonstructural Proteins | 2020 |
A Favipiravir-induced Fever in a Patient with COVID-19.
Topics: Aged, 80 and over; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Fever; Humans; Male; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2 | 2020 |
A case of COVID-19 pneumonia successfully treated with favipiravir (Avigan) in which serum SARS-CoV-2 RNA detected by LAMP method was clinically useful.
Topics: Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Humans; Male; Middle Aged; Molecular Diagnostic Techniques; Nasopharynx; Nucleic Acid Amplification Techniques; Pneumonia, Viral; Pyrazines; Respiration, Artificial; RNA, Viral; SARS-CoV-2; Treatment Outcome; Viremia | 2021 |
Fingernail lunula luminescence in COVID-19 patients: Is it a favipiravir-related reaction or a novel manifestation of coronavirus infection.
Topics: Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Luminescence; Nails; Pneumonia, Viral; Pyrazines; SARS-CoV-2; Turkey; Ultraviolet Rays | 2021 |
A case report of super responder of critical COVID-19 pneumonia.
Topics: Aged; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Critical Illness; Drug Therapy, Combination; Glucocorticoids; Humans; Lung; Male; Methylprednisolone; Pneumonia, Viral; Pyrazines; Receptors, Interleukin-6; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2021 |